Avidity Biosciences, Inc. (RNA)

Market Cap	3.91B
Revenue (ttm)	10.90M
Net Income (ttm)	-322.30M
Shares Out	120.21M
EPS (ttm)	-2.89
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	832,590
Open	32.03
Previous Close	32.05
Day's Range	32.03 - 33.13
52-Week Range	21.56 - 56.00
Beta	1.02
Analysts	Strong Buy
Price Target	68.25 (+109.61%)
Earnings Date	May 8, 2025

About RNA

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company’s product candidate Delpacibart etedesiran is for the treatment of myotonic dystrophy type 1 and is currently in phase 3 trial. Its other products in pipeline include Delpacibart zotadirsen for the treatment of duchenne muscular dystrophy, which is under phase 2 clinical development trial; and Delpac...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 12, 2020
• Employees: 391
• Stock Exchange: NASDAQ
• Ticker Symbol: RNA
• Website: https://www.aviditybiosciences.com

Financial Performance

In 2024, Avidity Biosciences's revenue was $10.90 million, an increase of 13.99% compared to the previous year's $9.56 million. Losses were -$322.30 million, 51.9% more than in 2023.

Analyst Forecast

According to 12 analysts, the average rating for RNA stock is "Strong Buy." The 12-month stock price forecast is $68.25, which is an increase of 109.61% from the latest price.

Price Target

$68.25

(109.61% upside)

Analyst Consensus: Strong Buy